(Q47717093)

English

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Daniel Castellano

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Peter H O'Donnell

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Petros Grivas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jacqueline Vuky

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Thomas Powles

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Elizabeth R Plimack

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Noah M Hahn

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Ronald de Wit

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Lei Pang

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Mary J Savage

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Rodolfo F Perini

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Stephen M Keefe

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Dean Bajorin

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Joaquim Bellmunt

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

26 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1483-1492

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Urothelial carcinoma management in elderly or unfit patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Index for rating diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30616-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967485%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47717093&oldid=1516757856"